Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MVP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MVP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MVP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MVP_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MVP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MVP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MVP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MVP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005102822 | Thyroid | ATC | mRNA transport | 80/6293 | 130/18723 | 6.13e-11 | 1.99e-09 | 80 |
GO:000646925 | Thyroid | ATC | negative regulation of protein kinase activity | 114/6293 | 212/18723 | 1.06e-09 | 2.69e-08 | 114 |
GO:003367325 | Thyroid | ATC | negative regulation of kinase activity | 122/6293 | 237/18723 | 9.19e-09 | 1.94e-07 | 122 |
GO:0038127111 | Thyroid | ATC | ERBB signaling pathway | 71/6293 | 121/18723 | 1.31e-08 | 2.69e-07 | 71 |
GO:0007173111 | Thyroid | ATC | epidermal growth factor receptor signaling pathway | 63/6293 | 108/18723 | 1.15e-07 | 1.92e-06 | 63 |
GO:004677717 | Thyroid | ATC | protein autophosphorylation | 114/6293 | 227/18723 | 1.54e-07 | 2.49e-06 | 114 |
GO:004205916 | Thyroid | ATC | negative regulation of epidermal growth factor receptor signaling pathway | 21/6293 | 28/18723 | 8.94e-06 | 8.95e-05 | 21 |
GO:190118515 | Thyroid | ATC | negative regulation of ERBB signaling pathway | 23/6293 | 32/18723 | 1.09e-05 | 1.07e-04 | 23 |
GO:190118415 | Thyroid | ATC | regulation of ERBB signaling pathway | 45/6293 | 79/18723 | 1.68e-05 | 1.55e-04 | 45 |
GO:004205814 | Thyroid | ATC | regulation of epidermal growth factor receptor signaling pathway | 42/6293 | 73/18723 | 2.29e-05 | 2.02e-04 | 42 |
GO:003195211 | Thyroid | ATC | regulation of protein autophosphorylation | 26/6293 | 43/18723 | 2.76e-04 | 1.77e-03 | 26 |
GO:006109913 | Thyroid | ATC | negative regulation of protein tyrosine kinase activity | 20/6293 | 31/18723 | 4.20e-04 | 2.51e-03 | 20 |
GO:005073211 | Thyroid | ATC | negative regulation of peptidyl-tyrosine phosphorylation | 32/6293 | 59/18723 | 8.74e-04 | 4.72e-03 | 32 |
GO:006109712 | Thyroid | ATC | regulation of protein tyrosine kinase activity | 45/6293 | 90/18723 | 9.39e-04 | 5.04e-03 | 45 |
GO:001821211 | Thyroid | ATC | peptidyl-tyrosine modification | 156/6293 | 378/18723 | 1.01e-03 | 5.36e-03 | 156 |
GO:00181086 | Thyroid | ATC | peptidyl-tyrosine phosphorylation | 153/6293 | 375/18723 | 1.96e-03 | 9.48e-03 | 153 |
GO:00507305 | Thyroid | ATC | regulation of peptidyl-tyrosine phosphorylation | 108/6293 | 264/18723 | 7.50e-03 | 2.93e-02 | 108 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MVP | SNV | Missense_Mutation | | c.510G>C | p.Gln170His | p.Q170H | Q14764 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MVP | SNV | Missense_Mutation | | c.1234G>A | p.Glu412Lys | p.E412K | Q14764 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
MVP | insertion | Frame_Shift_Ins | novel | c.2374_2375insAAGGCCTTTTGCAATGGCTATTCCTGCTGCCCAGAAAGCT | p.Val792GlufsTer38 | p.V792Efs*38 | Q14764 | protein_coding | | | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
MVP | insertion | Frame_Shift_Ins | novel | c.874_875insA | p.Gly292GlufsTer55 | p.G292Efs*55 | Q14764 | protein_coding | | | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
MVP | insertion | In_Frame_Ins | novel | c.875_876insCTCTTCCTTTGAGCCCCAGTTTCAGTT | p.Gly292_Lys293insSerSerPheGluProGlnPheGlnPhe | p.G292_K293insSSFEPQFQF | Q14764 | protein_coding | | | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
MVP | insertion | Frame_Shift_Ins | novel | c.2596_2597insAGGTGAGAGTTGGGGAAGGTGTGTTGGTTTCAGGA | p.Pro866GlnfsTer43 | p.P866Qfs*43 | Q14764 | protein_coding | | | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
MVP | insertion | Frame_Shift_Ins | rs778534743 | c.1744dupG | p.Ala582GlyfsTer9 | p.A582Gfs*9 | Q14764 | protein_coding | | | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
MVP | SNV | Missense_Mutation | novel | c.2012C>T | p.Ala671Val | p.A671V | Q14764 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MVP | SNV | Missense_Mutation | novel | c.10N>A | p.Glu4Lys | p.E4K | Q14764 | protein_coding | tolerated(0.15) | benign(0.08) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MVP | SNV | Missense_Mutation | | c.2641N>G | p.Gln881Glu | p.Q881E | Q14764 | protein_coding | tolerated_low_confidence(0.21) | benign(0) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |